Dapagliflozin in Patients With Type 2 Diabetes and Established Cardiovascular Disease: Hypotension and Volume-related Safety

被引：0
|
作者：
de Bruin, Tjerk W. [1 ]
Leiter, Lawrence A. [2 ]
Cefalu, William T. [3 ]
Gause-Nilsson, Ingrid [4 ]
Johnsson, Eva [4 ]
Parikh, Shamik J.
机构：
[1] AstraZeneca, Res & Dev, Wilmington, DE USA
[2] St Michaels Hosp, Div Endocrinol & Metab, Toronto, ON M5B 1W8, Canada
[3] Louisiana State Univ Syst, Pennington Biomed Rsch Cntr, Baton Rouge, LA USA
[4] AstraZeneca, Res & Dev, Molndal, Sweden
来源：
CIRCULATION | 2013年 / 128卷 / 22期
关键词：
Antihypertensive agents; Blood pressure; Cardiovascular disease; Diuretics; Older population;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
10677
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Dapagliflozin for Type 2 Diabetes Mellitus Patients With a History of Cardiovascular Disease
    Leiter, Lawrence A.
    Cefalu, William T.
    Debruin, Tjerk W.
    Gausenilsson, Ingrid
    Sugg, Jennifer
    Parikh, Shamik J.
    [J]. DIABETES, 2012, 61 : A287 - A287
  • [2] Efficacy and safety of dapagliflozin treatment for type 2 diabetes mellitus patients with comorbid cardiovascular disease and hypertension
    Cefalu, W.
    Leiter, L.
    De Bruin, T.
    Gause-Nilsson, I.
    Sugg, J.
    Parikh, S.
    [J]. DIABETOLOGIA, 2012, 55 : S305 - S305
  • [3] Long-term Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes, Cardiovascular Disease, and Hypertension
    Cefalu, William T.
    Gause-Nilsson, Ingrid Ami
    De Bruin, Tjerk W. A.
    Sugg, Jennifer E.
    Parikh, Shamik J.
    Johnsson, Eva
    [J]. DIABETES, 2014, 63 : A286 - A286
  • [4] Blood Pressure Reduction With Dapagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
    Woo, Vincent
    Leiter, Lawrence A.
    Cefalu, William T.
    de Bruin, Tjerk W.
    Gause-Nilsson, Ingrid
    Parikh, Shamik J.
    Johnsson, Eva
    [J]. CIRCULATION, 2013, 128 (22)
  • [5] Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes
    Al-Bazz, Dalai Y.
    Wilding, John P. H.
    [J]. FUTURE CARDIOLOGY, 2020, 16 (02) : 77 - 88
  • [6] Cardiovascular Outcomes with Dapagliflozin for Patients with Type 2 Diabetes
    Pavlicek, Vojtech
    [J]. DIABETOLOGE, 2019, 15 (03): : 262 - 264
  • [7] Dapagliflozin treatment for type 2 diabetes mellitus patients with a history of cardiovascular disease
    Leiter, L.
    Cefalu, W.
    DeBruin, T.
    Gause-Nilsson, I.
    Sugg, J.
    Parikh, S.
    [J]. DIABETOLOGIA, 2012, 55 : S310 - S311
  • [8] Two-year efficacy and safety of dapagliflozin for patients with type 2 diabetes mellitus and a history of cardiovascular disease
    Gause-Nilsson, I.
    DeBruin, T. W.
    Sugg, J.
    Parikh, S. J.
    Johnsson, E.
    Leiter, L. A.
    [J]. DIABETOLOGIA, 2014, 57 : S325 - S325
  • [9] Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
    Reifsnider, Odette S.
    Kansal, Anuraag R.
    Gandhi, Pranav K.
    Cragin, Lael
    Brand, Sarah B.
    Pfarr, Egon
    Fahrbach, Kyle
    Ustyugova, Anastasia
    [J]. BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [10] Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece
    Gourzoulidis, George
    Tzanetakos, Charalampos
    Ioannidis, Ioannis
    Tsimihodimos, Vasilis
    Diogo, Viana
    Karpouzos, George
    Papageorgiou, Giannis
    Kourlaba, Georgia
    [J]. CLINICAL DRUG INVESTIGATION, 2021, 41 (04) : 371 - 380
12345